<DOC>
	<DOCNO>NCT00781391</DOCNO>
	<brief_summary>This study demonstrate safety efficacy profile , two different dose regimen Edoxaban ( DU-176b ) , ( investigational new drug test prevention stroke/systemic embolic event ( SEE ) ) , individual atrial fibrillation . Patients randomize one three treatment group : High Dose Regimen , Low Dose Regimen , &amp; Warfarin . The expected duration study 24 month .</brief_summary>
	<brief_title>Global Study Assess Safety Effectiveness Edoxaban ( DU-176b ) v Standard Practice Dosing With Warfarin Patients With Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>21 year age old ; male female . Able provide write informed consent . History document AF within prior 12 month A moderate high risk stroke , define CHADS2 index score least 2 Transient atrial fibrillation secondary reversible disorder Subjects moderate severe mitral stenosis , unresected atrial myxoma , mechanical heart valve Subjects contraindication anticoagulant agent ; Subjects condition associate high risk bleed know suspected hereditary acquire bleed disorder Females childbearing potential include following : Females history tuballigation Females le 2 year postmenopausal</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Systemic embolic event</keyword>
</DOC>